• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, August 27, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

AI gets access to big novel chemistry space for quick and effective drug discovery

Bioengineer by Bioengineer
October 15, 2019
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: Insilico Medicine


San Diego (CA) – Insilico Medicine, in collaboration with ChemDiv, Inc., launched a drug discovery initiative that aims to use the power of artificial intelligence for screening chemistry space with newly designed compounds. The initiative is expected to identify a massive of drug candidates in the early stages. That became possible because AI can scan a vast number of compounds at higher speeds and with improved accuracy compared to traditional screening projects. The new project is aimed at rapidly screening targets in various therapeutic areas, including oncology, metabolism, immunology, urology, and others.

“We have successfully identified early drug candidates by screening a limited number of compounds with our AI virtual screening platform,” said Alex Zhavoronkov, Ph.D., Founder and CEO of Insilico Medicine. “ChemDiv significantly increases our capabilities by opening a great lead-like and drug-like novel chemical space with reliable support. Our joint effort to evaluate these diverse compounds increases the likelihood of developing new drugs for existing targets with less adverse effects.”

“We are connecting AI technology with ChemDiv’s efforts and investments in the design and validation of novel chemistry,” said Sergey Bugrov, Executive Director, ChemDiv. “The feasible chemical space of 3 billion molecules partitioned in validated unique scaffolds and available for modeling is represented by 1.7 million physical compounds. This new approach, will immediately provide researchers with many more starting points for drug discovery and significantly improve their process”.

###

About ChemDiv

ChemDiv is a recognized global leader in drug discovery solutions. Over the past 29 years, ChemDiv has delivered hundreds of leads, drug candidates and new drugs in the area of CNS, oncology, virology, inflammation, cardiometabolic and immunology, to pharma, biotech and academic partners around the globe. [http://www.chemdiv.com]

About Insilico Medicine

Insilico Medicine is an artificial intelligence company headquartered in Hong Kong, with offices in six countries and regions. The Company was the first to apply the generative adversarial networks (GANs) and reinforcement learning (RL) to generate new molecular structures with the specified parameters in 2015. In addition to collaborating with large pharmaceutical companies, Insilico Medicine is also pursuing internal drug discovery programs in different disease areas and anti-aging fields. Recently, Insilico Medicine published some of the results in Nature Biotechnology and secured $37 million in series B funding. Website http://insilico.com/

Media Contacts

For further information, images or interviews, please contact: Please contact

Insilico Medicine: Klug Gehilfe [email protected]

ChemDiv: Ron Demuth, [email protected]

Media Contact
Klug Gehilfe
[email protected]

Tags: BiochemistrycancerCollaborationHealth CareMedicine/HealthPharmaceutical SciencesPharmaceutical/Combinatorial ChemistrySoftware EngineeringTheory/Design
Share12Tweet8Share2ShareShareShare2

Related Posts

Ethical Considerations in Out-of-Sequence Organ Allocation

August 27, 2025

Enhancing Diabetes Care: A Lab-Driven Quality Initiative

August 27, 2025

HMGB1 and TLR4: New Biomarkers for Osteoporosis Risk

August 27, 2025

Revolutionizing Precision Medicine with Advanced Pharmacometric Tools

August 27, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    148 shares
    Share 59 Tweet 37
  • Molecules in Focus: Capturing the Timeless Dance of Particles

    142 shares
    Share 57 Tweet 36
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    115 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    81 shares
    Share 32 Tweet 20

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Ethical Considerations in Out-of-Sequence Organ Allocation

Enhancing Diabetes Care: A Lab-Driven Quality Initiative

HMGB1 and TLR4: New Biomarkers for Osteoporosis Risk

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.